Preclinical data also have shown that the combination of PD-L1 antibody and ibrutinib suppresses tumour growth in mouse models of lymphoma, triple-negative breast cancer, and colon cancer, most likely due to inhibition of Itk on T cells and in a Btk-independent manner [93]. This evidence concerns the gene CD274 and neoplasm.